About: QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019
Creator	Nguyen, Dan Green, Margaret Roth, Gregory Johnston, Christine Chatterjee, Neal Poole, Jeanne Saour, Basil Sridhar, Arun Starnes, Elizabeth
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: The arrhythmic safety profile of HCQ monotherapy, which remains under investigation as a therapeutic and prophylactic agent in COVID-19, is less established and we sought to evaluate this. METHODS: In 245 consecutive patients with COVID-19 admitted to the University of Washington hospital system between March 9 and May 10, 2020, we identified 111 treated with HCQ monotherapy. Patients treated with HCQ underwent a systematic arrhythmia and QT interval surveillance protocol including serial electrocardiograms (ECG) (baseline, following second HCQ dose). The primary endpoint was in-hospital sustained ventricular arrhythmia or arrhythmic cardiac arrest. Secondary endpoints included clinically significant QTc prolongation. RESULTS: A total of 111 patients with COVID-19 underwent treatment with HCQ monotherapy (mean age 62±16 years, 44 women [39%], serum creatinine 0.9 [interquartile range 0.4] mg/dL). There were no instances of sustained ventricular arrythmia or arrhythmic cardiac arrest. In 75 patients with serial ECGs, clinically significant QTc prolongation was observed in a minority (N=5 [7%]). In patients with serial ECGs, there was no significant change in the QTc interval in pre-specified subgroups of interest, including those with prevalent cardiovascular disease or baseline use of renin-angiotensin-aldosterone axis inhibitors. CONCLUSION: In the context of a systematic monitoring protocol, HCQ monotherapy in hospitalized COVID-19 patients was not associated with malignant ventricular arrhythmia. A minority of patients demonstrated clinically significant QTc prolongation during HCQ therapy.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1016/j.hroo.2020.06.002
bibo:pmid	32835316
has license	no-cc
sha1sum (hex)	a6242836403690b2ebca0fa1e616a044caddc9e7
schema:url	https://doi.org/10.1016/j.hroo.2020.06.002
resource representing a document's title	QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019
has PubMed Central identifier	PMC7289101
has PubMed identifier	32835316
schema:publication	Heart Rhythm O2
resource representing a document's body	covid:a6242836403690b2ebca0fa1e616a044caddc9e7#body_text
is schema:about of	named entity 'hydroxychloroquine' named entity 'INCREASED' named entity 'azithromycin' named entity 'Journal' named entity 'cardiovascular risk' named entity 'Coronavirus Disease 2019' named entity 'Monotherapy' named entity 'Hydroxychloroquine' named entity 'QT prolongation' named entity 'QT prolongation' named entity 'comorbidities' named entity 'Institutional Review Board' named entity 'ECGs' named entity 'HCQ' named entity 'HCQ' named entity 'arrhythmia' named entity 'intensive care unit' named entity 'QT interval' named entity 'heart rate' named entity 'monotherapy' named entity 'HCQ' named entity 'ventricular arrhythmia' named entity 'monotherapy' named entity 'HCQ' named entity 'HCQ' named entity 'clinically significant' named entity 'HCQ' named entity 'HCQ' named entity 'QTcH' named entity 'serum creatinine' named entity 'fluoroquinolone' named entity 'COVID' named entity 'angiotensin' named entity 'QTc' named entity 'IRB' named entity 'electrolyte abnormalities' named entity 'QT interval' named entity 'QTc interval' named entity 'HCQ' named entity 'arrhythmia' named entity 'ECG' named entity 'COVID' named entity 'HCQ' named entity 'serum creatinine' named entity 'University of Washington' named entity 'COVID' named entity 'malignant' named entity 'caregiver' named entity 'sensitivity analysis' named entity 'malignant' named entity 'monotherapy' named entity 'monotherapy' named entity 'hERG' named entity 'retrospective chart review' named entity 'msec' named entity 'electrolyte abnormalities' named entity 'angiotensin' named entity 'follow-up' named entity 'intensive care unit' named entity 'atrial fibrillation' named entity 'ECG' named entity 'arrhythmia' named entity 'QTc' named entity 'healthcare providers' named entity 'QTcH' named entity 'atrial tachycardia' named entity 'HCQ' named entity 'malignant' named entity 'QTc interval' named entity 'HCQ' named entity 'accelerated idioventricular rhythm' named entity 'QTc' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software